| ¿µ¹® | gene | ÇÑ±Û | À¯ÀüÀÚ |
|---|---|---|---|
| ¼³¸í | À¯ÀüÀÚ´Â ±æ°Ô ¶ì¸¦ Çü¼ºÇÑ DNAºÐÀÚÀÇ ÀϺκÐÀ¸·Î ÇÑ °¡Áö ¹°ÁúÀ» ¸¸µå´Âµ¥ ÇÊ¿äÇÑ ¸ðµç Á¤º¸¸¦ °®Ãá ±â´ÉÀûÀÎ ´ÜÀ§ÀÌ´Ù. ¿¹¸¦ µé¾î Àν¶¸°À̶ó´Â ¹°ÁúÀÇ À¯ÀüÀÚ¶ó°í ÇÏ¸é »ç¶÷ÀÇ ¼¼Æ÷³»¿¡ ÀÖ´Â ±ä DNA ºÐÀÚ Áß¿¡¼ Àν¶¸°À̶ó´Â ¹°ÁúÀ» ¸¸µå´Âµ¥ ÇÊ¿äÇÑ ¸ðµç Á¤º¸¸¦ °¡Áö°í ÀÖ´Â ÇÑ ºÎºÐÀ» °¡¸®Å°´Â ¸»ÀÌ´Ù. °íÀüÀûÀÎ »ý¹°Çп¡¼´Â À¯ÀüÀÚ°¡ Ç¥ÇöÇüÀ» °áÁ¤Çϰųª ÁöÁ¤ÇÏ´Â ¿°»öüÀÇ ÀϺκÐÀ̶ó°í Á¤ÀǵǾúÁö¸¸, ¿À´Ã³¯¿¡´Â À¯ÀüÀÚ¿¡ ´ëÇØ¼ ºÐÀÚÀû Á¤Àǰ¡ Á¦¾ÈµÇ°í ÀÖÀ¸¸ç ±× Á¤ÀÇ´Â ÇϳªÀÇ À¯ÀüÀÚ´Â ÇϳªÀÇ È¿¼Ò¸¦ °áÁ¤ ¶Ç´Â ¾ÏÈ£ÈÇÏ´Â À¯Àü¹°ÁúÀÇ ÀϺκÐÀ̶ó´Â °³³äÀ¸·Î À̰ÍÀÌ À̸¥¹Ù 1°³ÀÇ À¯ÀüÀÚ 1°³ È¿¼Ò°¡¼³(one gene-one enzyme hypothesis)ÀÌ´Ù. Áï 1°³ÀÇ À¯ÀüÀÚ´Â 1°³ÀÇ È¿¼Ò¸¦ Á¦ÀÛÇϴµ¥ ÇÊ¿äÇÑ À¯ÀüÁ¤º¸¸¦ °¡Áø´Ù´Â °ÍÀÌ´Ù. ÇöÀç ÀÌ °¡¼³ÀÌ ¹Þ¾Æµé¿©Áö°í ÀÖ´Ù. |
||
| ¿µ¹® | gene therapy | ÇÑ±Û | À¯ÀüÀÚ¿ä¹ý |
|---|---|---|---|
| ¼³¸í | À¯Àüº´À» Ä¡·áÇÒ ¸ñÀûÀ¸·Î, Á¤»óÀûÀ¸·Î ±â´ÉÇÏ´Â ´ÜÀÏÀ¯ÀüÀÚ È¤Àº º¹¼öÀ¯ÀüÀÚ¸¦ ¾î¶² ±â¿ø¿¡¼ ¾ò¾î³»¾î »ý¼¼Æ÷¿¡ µµÀÔÇÏ´Â °Í. À¯Àü¹°ÁúÀº À¯ÀüÀÚ»ðÀÔ Á¶ÀÛ¿¡ ÀÇÇØ ¼ö¿ë¼¼Æ÷¿¡·Î µµÀԵȴÙ. Áï, À¯ÀüÀÚ¸¦ ³¢¿ö ³ÖÀº »õ·Î¿î ¼¼Æ÷¸¦ »ç¿ëÇÏ´Â Ä¡·á·Î¼ 1980³â ¹Ì±¹ÀÇ ÇÐÀÚ°¡ ÁöÁßÇØºóÇ÷ȯÀÚ¿¡°Ô °ÇàÇÏ¿© ºñÆÇÀ» ¹Þ¾ÒÁö¸¸, ¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¼Ò´Â 1990³â 9¿ù ¾Æµ¥³ë½Å µ¥¾Æ¹Ì³ª¾ÆÁ¦(adenosine deaminase, ADA) °áÇÌÁõ ȯÀÚÀÇ ¸²ÇÁ±¸¿¡ ADA À¯ÀüÀÚ¸¦ ³¢¿ö ³Ö´Â Ä¡·á¸¦ ½ÃÀÛÇÑ ÀÌ·¡ ÇöÀç´Â ¾ÏÀ» Æ÷ÇÔÇÑ ¸¹Àº Áúº´µéÀ» Ä¡·áÇÏ´Â ¸ñÀûÀ¸·Î ¾²ÀδÙ. |
||
| ¿µ¹® | ovarian cancer | ÇÑ±Û | ³¼Ò¾Ï |
|---|---|---|---|
| ¼³¸í | ¿©¼ºÀÇ ³¼Ò¿¡ ¹ß»ýÇÏ´Â ¾Ï. ºÎÀΰúÁ¾¾çÀ¸·Î¼ 50¼¼ ÀÌ»ó ¿©¼º¾Ç¼ºÁ¾¾çÀÇ ¾à 18%¸¦ Â÷ÁöÇÑ´Ù. Á¾¾çÀº ´ë°³ º¹ºÎ ±í¼÷È÷ À§Ä¡ÇϹǷΠÁ¾¾çÀÌ ¸¹ÀÌ ÁøÇàµÈ »óÅ¿¡¼ ¹ß°ßµÇ´Â ¼ö°¡ ¸¹À¸¸ç, ¶ÇÇÑ Á¾¾çÀÇ Ãʱ⿡´Â Áõ»óÀÌ °ÅÀÇ ¾ø´Â °æ¿ì°¡ ¸¹¾Æ ´õ¿í Á¶±â¹ß°ßÀÌ ¾î·Æ´Ù. ¾ÆÁÖ ´Ù¾çÇÑ Á¾·ùÀÇ ¾ÏÀÌ ¹ß»ýÇϸç, ¿¹Èĵµ °¢±â ±× Á¾¾çÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£´Ù. ´ëÇ¥ÀûÀÎ ¾ÏÀ¸·Î À强³¶»ù¾ÏÁ¾(serous cystadenocarcinoma), Á¡¾×³¶»ù¾ÏÁ¾(mucinous cystadenocarcinoma), Á¾ÀÚ¼¼Æ÷Á¾(germinoma µîÀÌ ÀÖ´Ù. Ä¡·á´Â ¼ö¼úÀû Ä¡·á°¡ ¼±ÇàµÇ¾î¾ß ÇÏÁö¸¸, ¸¹ÀÌ ÁøÇàµÇ¾î ÀÌ¹Ì ´Ù¸¥ Á¶Á÷À¸·Î ÀüÀ̰¡ ÀÌ·ç¾îÁø »óÅ¿¡¼´Â ÈÇпä¹ýÀÌ ¼±ÅÃÀûÀ¸·Î »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | cancer | ÇÑ±Û | ¾Ï |
|---|---|---|---|
| ¼³¸í | ³¡¾øÀÌ ºÐ¿À» ÇÏ¿© Ç÷¾×À̳ª ¸²ÇÁ°üÀ» ÅëÇÏ¿© ´Ù¸¥ Àå±â¿¡±îÁö ÀüÆÄµÉ ¼ö ÀÖ´Â ¼¼Æ÷ÀÇ µ¢¾î¸®. Áï ¾Ç¼º ½Å»ý¹°À» ¸»ÇÑ´Ù. ½Å»ý¹°Àº ¾Ç¼º°ú ¾ç¼ºÀÌ Àִµ¥, ¾Ç¼ºÀÏ °æ¿ì¿¡´Â ¼ºÀåÀÌ ¸Å¿ì ºü¸£°í Ç÷¾×À̳ª ¸²ÇÁ°üÀ» ÅëÇØ¼ ¸Ö¸® ´Ù¸¥ ¶³¾îÁø Àå±â·Î ¾Ï¼¼Æ÷ÀÇ ÀüÆÄ°¡ °¡´ÉÇÏ¿© ´Ù¸¥ Àå±â¿¡µµ ¾ÏÀ» ÀüÀÌÇϸç, ¾ç¼ºÀº õõÈ÷ ÀÚ¶ó°í ´Ù¸¥°÷À¸·Î ÀüÀ̰¡ »ý±âÁö ¾Ê´Â´Ù. ¾ÏÀº ¾ÏÁ¾°ú À°Á¾ÀÇ µÎ °¡Áö·Î ³ª´ ¼ö°¡ ÀÖ´Ù. ¾ÏÁ¾À̶õ »óÇǼ¼Æ÷ÀÇ °úµµÇÑ Áõ½Ä¿¡ ÀÇÇÑ ¾Ç¼º½Å»ý¹°À» À̸£´Â ¸»À̰í À°Á¾À̶õ ºñ»óÇǼº¼¼Æ÷ ƯÈ÷ Áß°£¿±¼¼Æ÷(¹ß»ý´ç½Ã¿¡ Áß°£¿±¿¡ ÇØ´çÇÏ´Â Á¶Á÷À¸·Î ¹ß»ýÈÄ¿¡ Á¶Á÷»çÀÌ¿¡ ºÐÆ÷ÇÏ¸é¼ Á¶Á÷À» ÁöÁöÇÏ´Â ¿ªÇÒÀ» ÇÏ´Â °áÇÕÁ¶Á÷, Ç÷°ü, ¸²ÇÁ°ü µîÀÌ µÈ´Ù)ÀÇ °úµµÇÑ Áõ½Ä¿¡ ÀÇÇÑ ¾Ç¼º ½Å»ý¹°À» À̸£´Â ¸»ÀÌ´Ù. |
||
| ¿µ¹® | cancer surgery | ÇÑ±Û | ¾Ï ¼ö¼ú |
|---|---|---|---|
| ¼³¸í | ¾ÏÀÇ 4´ë Ä¡·á¹ýÀº ¿Ü°úÀû ¼ö¼ú¿ä¹ý, ¹æ»ç¼± Ä¡·á¹ý, Ç×¾Ï ÈÇпä¹ý, ¸é¿ª¿ä¹ý µîÀ» ¸»Çϸç ÀÌÁß ¼ö¼ú¿ä¹ý°ú ¹æ»ç¼± ¿ä¹ýÀº ±¹¼ÒÀû ¿ä¹ýÀ¸·Î¼ ¾Ï¼¼Æ÷°¡ ¿ø¹ßÀå±â(óÀ½ ¾ÏÀÌ ¹ß»ýÇÑ Àå±â)³ª ±¹¼Ò ¸²ÇÁÀý±îÁö ±¹ÇѵǾî ÀÖ´Â Á¦ 1, 2±â ¾ÏÀÇ Ä¡·á¿¡ »ç¿ëµÈ´Ù. ÈÇпä¹ý°ú ¸é¿ª¿ä¹ýÀº Àü½Å¿ä¹ýÀ¸·Î¼ Á¦ 3, 4±â ¾Ï¿¡ ÁÖ·Î »ç¿ëµÇ¸ç, 1, 2±â ¾ÏÀÇ Ä¡·á ÈÄ ´«¿¡ º¸ÀÌÁö ¾Ê°Ô ³²¾Æ ÀÖÀ» ¼ö ÀÖ´Â ÀÜ·ù¾Ï¼¼Æ÷³ª ¹Ì¼¼ÀüÀÌ ¾Ï¼¼Æ÷ÀÇ ¿ÏÀüÆÄ±«, »ç¸êÀ» À§ÇØ »ç¿ëµÈ´Ù. ¹éÇ÷º´, ¸²ÇÁÁ¾°ú °°ÀÌ ÈÇпä¹ýÁ¦¿¡ Àß µè´Â Ç÷¾×¾Ï, ¸²ÇÁÁ¾°ú °íȯÁ¾°ú °°ÀÌ ¹æ»ç¼± Ä¡·á¿¡ Àß µè´Â ¾ÏÀ» Á¦¿ÜÇÑ ´ëºÎºÐÀÇ °íÇü¾Ï(solid tumor)ÀÎ À§Ã¢ÀÚ°ü¾Ï, °£¾Ï, ÀÌÀÚ¾Ï, À¯¹æ¾Ï, °©»ó»ù¾Ï, Æó¾Ï, Èæ»öÁ¾, ¿¬Á¶Á÷¾Ï, »ÀÀ°Á¾, ħ»ù¾Ï µîÀº ¸ðµÎ ¼ö¼ú¿ä¹ýÀ¸·Î Ä¡·áÇÏ¿©¾ß ÇÑ´Ù. ¾Ï¼ö¼úÀÇ ±âº»¿øÄ¢: ¾Ï¼ö¼úÀÇ 3°¡Áö ±âº»¿ä°ÇÀº ¾ÈÀü¼º, ±ÙÄ¡¼º, ±â´Éº¸Á¸¼ºÀÌ¸ç ¾Ï¼ö¼ú½Ã¿¡´Â ¾Ïº´Å͸¦ µÇµµ·Ï Á¶½ÉÇØ¼ Àû°Ô ¸¸Áö¸é¼ ¼ö¼úÇÏ°í ¾Ïº´Å͸¦ °ø±ÞÇÏ´Â µ¿Á¤¸Æ°ú ¸²ÇÁ°üÀ» ¸ÕÀú °áÂûÇÏ¿© ¾Ïº´ÅͰ¡ ÆÛÁö´Â °ÍÀ» ¹æÁöÇÑ´Ù. ¾Ï¼ö¼úÀÇ ¸ñÇ¥´Â ±ÙÄ¡Àû ÀýÁ¦¼ö¼ú(radical surgery)ÀÌ´Ù. ±×·¯³ª À̰ÍÀÌ ºÒ°¡´ÉÇÑ È¯ÀÚ¿¡¼´Â ÃâÇ÷, Æó»ö, õ°ø µîÀÇ ÇÕº´ÁõÀÌ ¹ß»ýÇßÀ»¶§ ±¸±Þ¸ñÀûÀ¸·Î ȤÀº Áö¼ÓÀû µ¿ÅëÀÌ ÀÖÀ»¶§ »ýȰ³»¿ëÀÇ ÁúÀû °³¼±À» À§ÇÏ¿© °í½ÄÀû ¼ö¼ú(palliative surgery)À» ÇÑ´Ù. ±×¸®°í ¾ÏÀÇ Á¤È®ÇÑ Áø´Ü°ú ÁøÇ൵ÀÇ °áÁ¤À» À§ÇÑ Áø´ÜÀû ¼ö¼ú(diagnostic surgery)ÀÌ ÀÖ´Ù. |
||
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
|---|---|
| MCC | mean corpuscular hemoglobin concentration; medial cell column; Medical Council of Canada; metacerebr... |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| CC | calcaneal-cuboid; calcium cyclamate; cardiac catheterization; cardiac contusion; cardiac cycle; card... |
| ICR | [distance between] iliac crests; Institute for Cancer Research; Institute for Cancer Research [mouse... |
| 16S rDNA | 16S rRNA gene |
|---|---|
| PGK | 3-phosphoglycerate kinase gene |
| CGRP | AM/calcitonin gene-related peptide |
| alpha-CGRP | Alpha calcitonin gene-related peptide |
| APO E | Apolipoprotein E gene |
| BRCA1 breast cancer susceptibility gene | This mutated (changed) version of the BRCA1 gene makes a person susceptible to developing breast cancer. (12 Dec 1998) |
|---|---|
| cancer susceptibility gene | tumour suppressor gene |
| American Cancer Society | <address, organisation> American Cancer Society, National Headquarters, 1599 Clifton Road, NE, Atlanta, GA 30329 USA. Tel: 00 1 404 320-3333 (05 Feb 1998) |
| bladder cancer | The most common warning sign of bladder cancer is blood in the urine. The diagnosis of bladder cancer is supported by findings in the medical history and examination, blood, urine, and X-ray tests, and confirmed with a biopsy (usually during a cystoscope exam). Treatment of bladder cancer depends on the growth, size, and location of the tumour. (12 Dec 1998) |
| bladder cancer risks | Smoking is a major risk factor. Cigarette smokers develop bladder cancer 2-3 times more often than do nonsmokers. Quitting smoking reduces the risk of bladder cancer, lung cancer, several other types of cancer, and a number of other diseases as well. Workers in some occupations are at higher risk of developing bladder cancer because of exposure to carcinogens (cancer-causing substances) in the workplace. These workers include people in the rubber, chemical, and leather industries, as well as hairstylists, machinists, metal workers, printers, painters, textile workers, and truck drivers. (12 Dec 1998) |
| bone cancer | <oncology> A general term to imply malignant tumour growth in bone. (27 Sep 1997) |
| bovine cancer eye | A malignant squamous cell carcinoma of cattle, especially the Hereford breed, that originates in the conjunctival mucous membranes or the surrounding skin; it occurs principally in range cattle having unpigmented skin around the eye and living in regions of intense sunlight. (05 Mar 2000) |
| breast cancer | <oncology> The uncontrolled growth of malignant breast tissue. Breast cancer is currently the most common cancer in women and the leading cause of cancer-related death in the 15-54 age group. Strong risk factors include a prior history for breast cancer or a positive family history for breast cancer. Early detection is possible through the use of monthly breast self-examination, annual clinical exams and mammography. WWW: cancerNET document for patients WWW: cancerNET document for clinicians (05 Jan 1998) |
| breast cancer susceptibility genes | Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. However, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered. (12 Dec 1998) |
| buyo cheek cancer | betel cancer |
| cancer | <oncology> The first historical description of this condition was in relation to breast carcinoma. This is now a general term for more than 100 diseases that are characterised by uncontrolled, abnormal growth of cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body. (18 Nov 1997) |
| cancer antigen 125 test | Test for cell-surface antigen found on derivatives of coelomic epithelium. Elevated levels of this antigen are associated with ovarian malignancy and benign pelvic disease such as endometriosis. (05 Mar 2000) |
| cancer, bladder | Cancer of the organ responsible for temporarily holding urine after it leaves the kidneys. The most common warning sign of cancer in the bladder (the hollow organ in the lower abdomen that stores urine) is blood in the urine. The diagnosis of bladder cancer is supported by findings of the medical history and examination, blood, urine, and X-ray tests, and confirmed with a biopsy (usually during a cystoscope exam). (12 Dec 1998) |
| cancer bodies | Discrete, acidophilic or amphophilic, hyaline body's of various shapes and sizes, occurring in the cytoplasm of some of the neoplastic cells and also extracellularly in the stroma of various carcinomas and sarcomas; formerly regarded by some observers as parasitic causal agents, but now thought to be products of cell necrosis (apoptosis). (05 Mar 2000) |
| cancer, bone | Cancer of the skeleton. Cancers that begin in bone are rare but it is not unusual for cancers to spread (metastasize) to bone from other parts of the body. This is not called bone cancer, but is named for the organ or tissue in which the cancer begins. Pain is the most frequent symptom of cancer of the bone. Diagnosis of cancer of the bone is supported by findings of the medical history and examination, blood and X-ray tests and confirmed with a biopsy. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|